BPIFB4

1. BPIFB4 inhibits p38 MAPK signalling in human cells.

   “selectively reducing p38 MAPK activation while leaving NF-κB signaling largely unaffected in response to LPS”

   Cellsin response to LPS

   The LAV-BPIFB4-Platelet-CD47 Axis: A Novel Mechanism Associated With Immune Resilience in Longevity

   Aging cell·25 Jun 2026

More on p38 MAPK signalling

1. BPIFB4 is associated with CD47+ reticulated platelets in humans.

   “centenarians displayed an elevated percentage of circulating CD47+ reticulated platelets (RPs), a condition mimicked by LAV-BPIFB4 carriers”

   Humansin centenarians and LAV-BPIFB4 carriers

   The LAV-BPIFB4-Platelet-CD47 Axis: A Novel Mechanism Associated With Immune Resilience in Longevity

   Aging cell·25 Jun 2026

More on CD47+ reticulated platelets

1. BPIFB4 is associated with NAD+ in humans.

   “Long-living-individuals (LLIs, >95 years), which delay CVDs onset, especially if LAV-carriers, were characterized by high NAD+ levels.”

   HumansLAV-carriers

   Transfer of the longevity-associated variant of BPIFB4 gene rejuvenates immune system and vasculature by a reduction of CD38⁺ macrophages and NAD⁺ decline

   Cell death & disease·27 Jan 2022

More on NAD+